SUNA and the American Urological Association (AUA) developed a joint Statement of Practice on Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer. The purpose of the statement is to define the performance guidelines surrounding the instillation of intravesical cytotoxic, immunotherapeutic, and/or therapeutic drugs via sterile technique catheterization for patients with non-muscle invasive bladder cancer (NMIBC, urothelial carcinoma).
Updated - 2020
Originally developed in July 2015, the paper was reviewed and revised in June 2020. 2020 Workgroup Members included Roxy Baumgartner, RN, APN-BC; Sam Chang, MD; Susan Flick, CNP; Howard Goldman, MD, FACS; Jim Kovarik, MS, PA-C; Yair Lotan, MD; Elspeth McDougall, MD, FRCSC, MHPE; Arthur Sagalowsky, MD; Edouard Trabulsi, MD; Debbie Hensley, RN; Christy Krieg, MSN, CUNP; and Leanne Schimke, MSN, CUNP
Download the Statement